The time to act against AMR is now.
“…the crisis of Anti-Microbial Resistance (AMR) threatens a century of progress in human medicine, and the health of animals, plants and the environment, as well as economies and livelihoods.”
– Mia Amor Mottley, Chair, Global Leaders Group on AMR.
• Our Vision
Niclosavir Ltd.
To improve the health and wellbeing of animals and people globally.
• Niclosavir Ltd.
Niclosavir is addressing this crisis with NicTek, our development platform that provides a sustainable, non-antibiotic alternative for controlling Staphylococcus aureus (including the MRSA superbug).
Niclosavir Limited is tackling one of the world’s most pressing challenges: Antimicrobial Resistance (AMR). AMR poses an existential threat to both human and animal health, and its impact is rapidly growing. As the misuse and overuse of antibiotics become a focal point in social, regulatory, and legal discussions, the need for sustainable solutions has never been clearer.
4.95 Million
Deaths linked to AMR in 2019, with 1.27 million directly attributed to antimicrobial resistance. 1
10 Million
Projected annual deaths by 2050 if no action is taken to combat AMR. 2
$1 Trillion
Annual loss (USD) in global GDP due to the economic impact of AMR. 3
7.5%
Projected reduction in global livestock production by 2050 due to AMR affecting animals. 4